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ABSTRACT
Importance: The effect of subconjunctival Bevaci-
zumab injection on the outcome of Ahmed glau-
coma valve (AGV) implantation.
Background: Evaluation of efﬁcacy and safety of
subconjunctival Bevacizumab injection adjunctive
to AGV implantation.
Design: Prospective and randomized clinical trial.
Participants: Fifty eyes of 50 patients with diagno-
sis of glaucoma that were candidate for AGV sur-
gery were included.
Methods: In 25 eyes, conventional AGV surgery
(group 1) and in 25 eyes AGV surgery with sub-
conjunctival Bevacizumab (group 2) was per-
formed by block randomization
Main Outcome Measures: The primary outcome
measure was surgical success. Outcome measures
were compared at postoperative month 3, 6
and 12.
Results: Mean age of patients was 58.76  12.11
and 51.36  15.44 years in group 1 and 2 respec-
tively (P = 0.06). Mean intraocular pressure (IOP)
at baseline was 24.88  7.62 mmHg in group
1 and 27.52  8.57 mmHg in group 2 which
decreased to15.4  4.4 mmHg in group 1 and
13.42  2.9 mmHg in group 2 (P < 0.00) at last fol-
low up. Surgical success was deﬁned in two level:
postoperative IOP ≤ 21 mmHg with at least 20%
reduction in IOP (Criterion A), either with no
medication (complete success) or with no more
than two medications (qualiﬁed success) and crite-
rion B with the same deﬁnition but the IOP ≤ 18
mmHg The cumulative success according to crite-
rion A and B was 77.8%, 72.2% in group 1 and
89.5% in group 2, respectively, at the end of
follow-up.
Conclusions and Relevance: Subconjunctival
injection of Bevacizumab adjunctive to AGV
implantation leads to higher success rate compared
with AGV alone in one year follow-up.
Key words: Ahmed glaucoma valve, Bevacizumab, ran-
domized control trial, subconjunctival injection.
INTRODUCTION
The role of aqueous shunts in modern glaucoma sur-
gery has been widely increased since the publica-
tion of Tube versus Trabeculectomy Study.1
Although a lot of studies evaluated the role of
antiﬁbrotic agents such as mitomycin C (MMC) and
5-ﬂuorouracil (5-FU) in trabeculectomy, there is
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little evidence on their role in shunt surgeries.2Th-
ese agents have increased the success of trabeculect-
omy especially in patients with poor prognosis; but
at the same time they have also increased the risk of
late-onset complications, such as bleb leaks, hypot-
ony and endophthalmitis.2–6There is large number
of evidence on the role of anti-VGEF agents in
reducing scar formation after glaucoma surgery, but
the effect of anti-VEGF agents on the shunt surgeries
is not clear yet.7
The success rate for tube shunts controlling vari-
ous types of refractory glaucoma has been reported
to be more than 50% in most previous series with
different success criteria and lengths of follow-up.1
Fibrovascular ingrowth into the valve chamber and
dense encapsulation around the plate are among a
probable causes of Ahmed glaucoma valve (AGV)
failure.7 Vascular endothelial growth factor (VEGF),
which is an endothelial cell-speciﬁc mitogen and an
angiogenic and also a ﬁbroblast proliferation
inducer, found to be an important stimulus for
wound healing.8–11 Bevacizumab (Bevacizumab;
Genentech, San Francisco, CA, USA) is a human-
ized, non-selective monoclonal antibody against
VEGF that commonly used in the ocular disease
with a vascular component.7 Studies showed that in
patients with diagnosis of glaucoma and especially
in neovascular glaucoma (NVG), VEGF concentra-
tion is increased in the aqueous humour.12 The ele-
vated VEGF levels in the aqueous humour can
trigger ﬁbrosis, 13 in the tissue around the plate
when the aqueous reaches to the subconjunctival
spaces after AGV implantation. It has been shown
that IVB pre-treatment can effectively increase the
complete success rate in NVG patients undergoing
AGV implantation surgery.14 Although the beneﬁ-
cial effect of Bevacizumab has been shown in neo-
vascular glaucoma the exact role of this agent in
other types of glaucoma has not been clariﬁed.14
The aim of the current study was to compare the
outcome of AGV implantation with and without
adjunctive Bevacizumab injection.
METHODS
This prospective, randomized clinical trial was per-
formed from April 2014 to July 2015 at Rassoul
Akram Hospital, Iran University of Medical sciences,
Tehran, Iran. Signed informed consent was obtained
from all patients, and the ethical committee of the
Iran University of Medical Sciences approved the
study. Patients with intraocular pressure (IOP) more
than 18 with full maximum tolerable medical treat-
ment were considered as uncontrolled. Also patients
with poor compliance to take medications were
included.
Only patients with at least 6 months of follow-up
were included in the statistical analysis.
The exclusion criteria were age younger than
18 years, those with active signs of ocular inﬂamma-
tion or NVG or being pregnant or currently breast-
feeding. The eyes were randomly chosen by
computer generated block randomization with block
size of 4 and assigned to two groups: conventional
AGV surgery (group 1) and surgery with sub con-
junctival Bevacizumab injection (group 2). Before
surgery, all participants underwent a comprehensive
ophthalmic examination, including slit-lamp biomi-
croscopy, best-corrected visual acuity (BCVA), IOP
measurement by a calibrated Goldmann applanation
tonometer, dilated funduscopy with a 90-diopter
lens and gonioscopy.
All surgeries were performed under either gen-
eral or retrobulbar anaesthesia by discretion of two
experienced surgeon (A.M. and N.N.).
We ﬁrst performed fornix-based peritomy in the
superotemporal quadrant. After priming of shunt
(AGV FP7, New World Medical) with balanced salt
solution, it was secured to the sclera with 8–0 nylon
sutures 9–10 mm behind the limbus. The tube was
trimmed bevelled up and then inserted into the
anterior chamber. The tube was then secured to
sclera with a 10–0 nylon suture and covered with a
donor sclera. Conjunctiva was closed with 10/0
vicryl in a running fashion at the end.
In the same fashion, AGV implantation was per-
formed in the Bevacizumab group, but after suturing
the conjunctiva, 2.5 mg (0.1 mL) Bevacizumab was
injected subconjunctivally at the site of the shunt
plate using 30-gauge needle. All patients were trea-
ted with ciproﬂoxacin eye drops four times a day for
10 days and betamethasone eye drops every 2–4 h
for 2 weeks that were tapered off slowly over
8–12 weeks. After surgery, antiglaucoma medica-
tions were added if necessary based on the targeted
IOP. Patients were scheduled for seven postopera-
tive follow-up visits within 6 months by assigned
resident who was blind to the treatment group: days
1, 7, 14, 30, 60, 90 and 180. After month 6, follow-
up visits were continued every 2 to 3 months. Suc-
cess was deﬁned in terms of IOP control based on
two criterion: Criterion A: 5 ≤ IOP < 22 mmHg with
at least ≥20% reduction in IOP without glaucoma
medication (complete success), or with no more than
two medications (qualiﬁed success). Cumulative
success was deﬁned as sum of complete and quali-
ﬁed success. Criterion B was deﬁned according to
criterion A but with IOP between 5 and 18 mmHg.
Failure was deﬁned when neither of the criteria was
achieved, visual acuity became no light perception
or reoperation was required.
Hypertensive phase was deﬁned as IOP > 21
mmHg during the ﬁrst 3 months after surgery after
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reduction of IOP to less than 21 mmHg during the
ﬁrst postoperative weeks.
Statistical analysis
Normal distribution of data was assessed by
Kolmogrov–Smirnov test and Q–Q plot.
Variables for statistical analysis included age, best
corrected visual acuity, success rates, IOP and num-
ber of medications. Group sample sizes of 25 and
25 achieve 81% power to detect a IOP difference of
2.0 mmHg between the mean post of IOP with esti-
mated group standard deviations of 2.5 and 2.4 and
with a signiﬁcance level (alpha) of 0.050 using a
two-sided two-sample t-test. Statistical analysis was
performed using SPSS software version 20. For the
purposes of analysis, data were reported as mean (
SD) and frequency. The Student t-test or Mann–
Whitney test was used to compare quantitative vari-
ables between two groups and Chi square test for
categorical variables to determine statistical signiﬁ-
cance. Statistical signiﬁcance was determined using
a, two-tailed test P value ≤ 0.05.
RESULTS
A total of 50 patients were enrolled in this study.
Ahmed valve was implanted in 25 eyes without
Bevacizumab (Group 1) and in 25 eyes with subcon-
junctival Bevacizumab injection (group 2). All of the
patients completed at least 6 months of follow-up
period. Demographic characteristics of patients are
summarized in Table 1. Both groups were compara-
ble in terms of age, sex, initial BCVA, and number
of glaucoma medications. Mean IOP at baseline was
24.88  7.62 mmHg in group 1 and 27.52  8.57
mmHg in group 2. (P = 0.25).
Mean follow-up was 10.32  2.74 months in
AVG alone and 10.56  2.61 in Bevacizumab
group (P = 0.25).
All patients had at least 6 months of follow-up
and 18 patients in group 1 and 19 patients in group
2 had completed 1 year of follow-up. In all post-OP
visits both groups showed statistically signiﬁcant
reductions in the mean IOP and in the mean num-
ber of glaucoma medications (P < 0.05)(Table 2)
However, there was no signiﬁcant difference
between the two groups at each time point except at
month 6 (P = 0.04). (Table 2) Number of medica-
tions decreased signiﬁcantly from 3.32  0.8 to
1.8  0.9 in 1 year in group 1 and from 3.48  0.65
to1.4  0.9 in group 2 (P < 0.00) but there was no
difference between the mean number of medications
at each time points between two groups. (Table 3).
Mean IOP was lower in Bevacizumab group dur-
ing 1 year of follow-up but the difference was sig-
niﬁcant only at month 6 (P < 0.04). (Table 3).
Tables 4 and 5 show the success rates based on
criterion A and B in both group at 6th and 12th
month visits.
The overall complication rate in both groups was
36%; the most common complication was shallow
AC, which observed in six cases. Table 6 displays
complication rates in each study group.
We had one case with choroidal detachment in
each group and one case with wound dehiscence in
group 2 which needed resuturing. No case of
endophthalmitis, suprachorodal haemorrhage or
plate exposure was observed. Hyphema was the
most common complication in group 2 (four cases)
Table 1. Patient demographics
Characteristics
Group 1
(conventional
AGV insertion)
Group 2
(AGV insertion
with Bevacizumab) P value
Age (mean  SD) (years) 58.76  12.11 51.36  15.44 0.06
Range: (25–73) Range: (21–81)
Sex (male %) 9/16 13/12 0.25
Laterality (right %) 52% 48% 0.77
Preoperative intraocular pressure (mmHg) 24.88  7.62 27.52  8.57 0.25
Range: (13–40) Range: (16–46)
Preoperative number of medications 3.32  0.80 3.48  0 0.65 0.545
Range: (2–4) Range (2–4)
Follow-up period (mean  SD) (months) 10.32  2.74 10.56  2.61 0.25
Range: (6–12) Range: (6–12)
Kind of glaucoma Primary open angle glaucoma 52% 40% 0.42
Chronic angle closure glaucoma 32% 28%
Pseudoexfoliation glaucoma 0% 12%
Congenital glaucoma 4% 0%
Post PK 0% 4%
Post vitrectomy 12% 16%
PK, penetrating keratoplasty.
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which resolved spontaneously in all cases. Hyper-
tensive phase deﬁned as IOP more than 21 mmHg
when initial IOP after surgery has reached to less
than 21 mmHg was observed in 60% in group 1 and
48% in group 2 during month 1 (P = 0.39) and in
24% and 12% in group 1 and 2 during month 1–3,
respectively (P = 0.39). There was no signiﬁcant
association between IOP before surgery and the
occurrence of hypertensive phase neither in ﬁrst
month nor in 3 months in both groups. (P = 0.67
and P = 0.77, respectively).
In multivariate regression analysis the only fac-
tor which has associated with failure was age in
group 1 (P < 0.03). The main reasons for failure
in group 1 with criterion A were: not reaching to
less than 20% decrease in IOP (three cases), IOP
more than 21 mmHg (two cases) and needing
more than two antiglaucoma medications (two
cases). In group two we had only one case of fail-
ure due to less than 20% decrease of IOP. We
had no failure due to hypotony or secondary
intervention.
Table 2. Comparison of pre and postoperative characteristics in each group
Group Characteristics Preoperative Postoperative (1 year) P value
Group 1 (conventional AGV insertion) Intraocular pressure (mmHg) 24.88  7.62 15.72  4.86 0.002
Range (mmHg) (13–40) (10–27)
Antiglaucoma medications number 3.32  0.80 1.82  0.92 0.001
Range (2–4) (0–2)
Best corrected visual acuity (logMAR) 0.94  0.79 0.87  0.83 0.67
Group 2 (AGV insertion with Bevacizumab) Intraocular pressure (mmHg) 27.52  8.57 14.00  3.52 <0.001
Range (mmHg) (16–46) (8–20)
Antiglaucoma medications number 3.48  0.65 1.42  0.90 <0.001
Range (2–4) (0–3)
Best corrected visual acuity (logMAR) 0.85  0.85 1.00  1.11 0.31
Table 3. Comparison between two groups in terms of intraocular pressure and medications at each time points of follow-up†
Pre-OP medication AGV (n = 25) 3.32  0 0.80 0.545
AGV + Bevacizumab (n = 25) 3.48  0.65
Post-OP 1 month medication AGV (n = 25) 1.20  1.04 0.32
AGV + Bevacizumab (n = 25) 0.92  0.95
Post-OP 3 months medication AGV (n = 25) 1.45  0.85 0.812
AGV + Bevacizumab (n = 25) 1.40  0.85
Post-OP 6 months medication AGV (n = 25) 1.68  0.80 0.310
AGV + Bevacizumab (n = 25) 1.44  0.86
Post-OP 12 months medication AGV (n = 18) 1.83  0.92 0.167
AGV + Bevacizumab (n = 19) 1.42  0.90
Pre-OP IOP AGV (n = 25) 24.88  7.62 0.25
AGV + Bevacizumab (n = 25) 27.52  8.57
Post-OP 1 month IOP AGV (n = 25) 18.20  7.26 0.83
AGV + Bevacizumab (n = 25) 17.80  6.48
Post-OP 3 months IOP AGV (n = 25) 16.86  3.68 0.07
AGV + Bevacizumab (n = 25) 14.40  5.09
Post-OP 6 months IOP AGV (n = 25) 16.52  4.29 0.04+
AGV + Bevacizumab (n = 25) 14.12  4.0137
Post-OP 12 months IOP AGV (n = 18) 15.72  4.86 0.22
AGV + Bevacizumab (n = 19) 14.00  3.52
†t-test + signiﬁcant.
Table 4. Success rates based on criterion a and B in Ahmed glaucoma valve implantation with or without subconjunctival Bevacizu-
mab injection at 6 months
Criterion Group Complete success Qualiﬁed success Cumulative success Failure
A Group 1 (conventional AGV insertion) 12% 56% 68% 32%
Group 2 (AGV insertion with Bevacizumab) 20% 72% 92% 8%
P value (Chi square) 0.034
B Group 1 (conventional AGV insertion) 12% 40% 52% 48%
Group 2 (AGV insertion with Bevacizumab) 20% 68% 88% 12%
P value (Chi square) 0.005
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DISCUSSION
Glaucoma is the second cause of blindness in the
world15 and trabeculectomy and tube shunt surgery
are the most common surgical procedure for manage-
ment of glaucoma. The efﬁcacy of a shunt surgery and
the level of IOP depends largely on the consistency
and permeability of capsule around the plate of
drainage device.16 The formation of thick vascular-
ized ﬁbrous capsule around the shunt decreases the
ﬁltration which may lead to surgical failure.7 The rate
of success after AGV implantation is different and
depends on the study design and type of glaucoma.
But on average approximately 50% of single-plate
AGV implantations in refractory glaucoma were con-
sidered successful after 5 years of follow-up.1,17
Antimetabolite application can signiﬁcantly
inhibit ﬁbrosis, and is widely used in drainage and
ﬁstulizing glaucoma surgeries.3,4 However, several
studies in the short and medium term follow-up
have showed ineffectiveness of mitomycin C in
improving success rate of shunt implantation both
in the short and in medium term follow-up.5,6
The purpose of this study was to evaluate the effect
of Bevacizumab as an antiangiogenic factor adjunctive
to AGV in controlling IOP in a randomized clinical
trial. VEGF stimulates multiple components of the
wound-healing cascade, such as angiogenesis, colla-
gen deposition and epithelization,8–11 all of them are
important risk factor for failure of glaucoma ﬁltration
surgeries.
Bevacizumab was approved by the US Food and
Drug Administration (FDA) in 2005 for the treatment
of colorectal and breast cancers, but it has also been
used as an off label treatment in several ocular condi-
tions such as neovascular glaucoma, age-related mac-
ular degeneration and diabetic retinopathy.18
Different routes of administration have been pro-
posed for application of anti-VEGF agents. Subcon-
junctival administrations offer direct modulation of
the conjunctival wound-healing process. In general,
after subconjunctival injection some of the Bevacizu-
mab may penetrate to intraocular tissues including
the retina/choroid, iris/ciliary body, and vitreous via
the sclera and also some is cleared via conjunctival
blood and lymphatic ﬂow.19
After subconjunctival injection of Bevacizumab,
the scleral matrix may work as a depot and causes
longer duration of exposure of iris, ciliary body to
this substance.19
Although optimal dose of subconjunctival Bevacizu-
mab is not clear, injections containing 1.25 or 2.5 mg
of drug were most commonly employed.17,18,20
We used subconjunctival Bevacizumab after ﬁn-
ishing shunt surgery and evaluated the effect of this
antiangiogenic agent on survival of shunt surgery
during the ﬁrst year of follow-up.
We observed lower IOP in Bevacizumab injection
group during follow up but the difference between
mean IOP was not signiﬁcant except at month 6 in
favour of Bevacizumab group. We observed 68%
cumulative success with Criteria A (IOP <21 mmHg)
on cases without injection and 96% in injection
group (P < 0.04). This demonstrates that Bevacizu-
mab enhances the survival in Ahmed valve in our
series in 1 year of follow-up. We considered criteria
B as IOP < 18 mmHg and found 60% cumulative
success in group 1 and 96% in group 2, respectively
(P < 0.01). Our success rate in Bevacizumab group
was a bit higher than previous published
studies.21–23
We found better success rate and lower number of
antiglaucoma medications in group 2 with Bevacizu-
mab injection. We observed hypertensive phase in
68% patients without injection of Bevacizumab and
52% of patients with injection (P > 0.05%), which is
not different from to previous published studies.17,24,25
Table 5. Success rate based on criterion A and B in Ahmed glaucoma valve implantation with or without subconjunctival Bevacizu-
mab injection at 12 months
Group Complete success Qualiﬁed success Cumulative success Failure
A Group 1 (conventional AGV insertion) 11% 66.8% 77.8% 22.2%
Group 2 (AGV insertion with Bevacizumab) 15.7% 73.8% 89.5% 10.5%
P value (Chi square) 0.405
B Group 1 (conventional AGV insertion) 11% 60.2% 72.2% 27.8%
Group 2 (AGV insertion with Bevacizumab) 15.7% 73.8% 89.5% 10.5%
P value (Chi square) 0.232
Table 6. Type of complications after Ahmed glaucoma valve
implantation with or without subconjunctival Bevacizumab
injection
Complications AGV
AGV +
Bevacizumab Total
Shallow AC 3 3 6
Choroidal detachment 2 0 2
Hypotonia 2 2 4
Hyphema 0 4 4
Leakage 0 1 1
Malignant glaucoma 0 1 1
Implant extrusion 0 0 0
Endophthalmitis 0 0 0
Total 7 (28%) 11 (44%) 18 (36%)
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Meanwhile we found no correlation between
hypertensive phase and age, sex and type of
glaucoma.
There were a few studies, which evaluated the
role of subconjunctival Bevacizumab in shunt sur-
gery. To the best of our knowledge it is the ﬁrst ran-
domized clinical trial comparing AGV implantation
with Bevacizumab with standard implantation sur-
gery in adult patients.
We found only one study which compared role of
subconjunctival Bevacizumab in shunt surgery in
paediatric glaucoma. In this study Mahdy used
1.25 mg of Bevacizumab subconjunctivally around
the valve body of Ahmed valve after ﬁnishing sur-
gery and compared it with mitomycin and placebo.
He observed 80% total success in ﬁrst group in
which Bevacizumab augmented Ahmed valve was
carried out in comparison with 90% total success in
group II in which MMC was used during Ahmed
valve implantation and this difference was not sig-
niﬁcant (P > 0.05), but in group III in which Ahmed
valve implanted without adjuvant, total success was
60% with no cases of qualiﬁed success, and this dif-
ference was statistically signiﬁcant to both groups I
and II (P < 0.05).
They concluded that both mitomycin and Bevaci-
zumab could increase valve survival but Bevacizu-
mab was safer compared to mitomycin.26. Rojo-
Arnao in a pilot study used subconjunctival Bevaci-
zumab in seven patients with Ahmed valve and
compared it with six case of shunt insertion without
injection. They showed that use of Bevacizumab
after 3 months can cause less hypertensive phase
after Ahmed valve surgery.27 In our study the rate of
hypertensive phase was not signiﬁcantly different
between two groups.
We observed only one case of leakage in Bevaci-
zumab group, which needed resuturing. We used
only non-absorbable sutures and no case of expo-
sure or protrusion occurred in 1 year.
In spite of increase in number of tube surgery
there is no absolute way for prevention of exces-
sive ﬁbrosis around the device yet. Although use
of antiﬁbrotic agents decrease scar formation after
trabeculectomy the same effect has not been docu-
mented after shunt surgery. Costa et al., in study
on 60 patients with refractory glaucoma used
intraoperative MMC (0.5 mg/mL for 5 min)
(n = 34) or balanced salt solution (n = 26) during
Ahmed glaucoma valve implantation. After mean
follow-up of 12.3 months Mitomycin C did not
increase the short- or intermediate-term success
rates of Ahmed glaucoma valve implantation.6 Yaz-
dani et al., in a randomized clinical trial compared
Ahmed valve implantation alone with Mitomycin
and wrapping of Ahmed valve in a amniotic mem-
brane as an anti-inﬂammatory agent and found no
inﬂuence from MMC and amniotic membrane on
success rate and hypertensive phase.28 Since ﬁbro-
blast function and growth of new vessels is a com-
ponent of healing of the bleb, there have been
attempts to retard this healing by the use of
Bevacizumab.
Li et al. reported that administration of Bevacizu-
mab signiﬁcantly inhibited VEGF-induced Tenon
ﬁbroblast proliferation in human (P = 0.04).7 Mem-
arzadeh et al. showed that in the rabbit subconjunc-
tival injection of Bevacizumab could increase bleb
survival.29 If we accept that VEGF directly stimu-
lates both vascular endothelial cells and ﬁbroblasts
and may be the link between angiogenesis and scar
formation, inhibition of VGEF can reduce ﬁbrosis
and may improve the success rates of the shunt sur-
gery in future.
As it mentioned previously our trial showed bet-
ter results with Bevacizumab than classic surgery.
The strength of the present analysis is that it is a
randomized clinical trial with direct comparison of
study groups.
We had limitations in our study. Small number
and heterogeneous type of study subjects and short
term of follow-up were among the main limitations
of this study. So more clinical trials with long term
follow-ups are necessary to show exact role of Beva-
cizumab in shunt surgery. In conclusion it seems
that Bevacizumab may lead to lower IOP and better
success during the ﬁrst year of surgery.
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